Nike Stock Rebound May Face Headwinds Analysts Cautious Oura Health Files Confidentially for IPO Signaling Growing Smart Ring Market Singapore Gains from AI Investment Boom but Faces Chip Supply Risks MTI Warns German Business Confidence Unexpectedly Rises Despite Energy Market Disruptions From Iran Conflict US Productivity Growth Slows in Q4 as Unit Labor Costs Rise Implications for Inflation and Fed Policy Info Edge Q4FY26 Results Consolidated Net Profit Up 22 YoY to Rs 566 Crore Revenue Climbs 16 Cadiz Inc Depositary Shares CDZIP Q1 2026 Earnings Narrower Loss Than Expected Amid Water Operations NUVB Q1 2026 Earnings Narrow EPS Beat Amid No Revenue and Stock Decline AA Q1 2026 Earnings EPS Misses Estimates Shares Climb on Strategic Optimism HSIC Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency VEON Q1 2026 Earnings EPS Beats Estimates Amid Operational Progress JHG Q1 2026 Earnings EPS Misses Estimates Amid Market Headwinds MV Oil Trust Units Edge Higher as Price Holds Above Key Support Insperity Inc NSP Surges 4 as Shares Test Key Resistance Zone Aqua Metals AQMS Edges Lower as Stock Approaches Critical Support Zone Clear Secure YOU Stock Slides 635 as Support Levels Come into Focus National Bankshares Inc NKSH Holds Steady Near Key Support Level JhunjhunwalaPartnered Fund Acquires Stake in Tourism Finance Corporation of India Management Discusses Outlook AIHS Q1 2026 Earnings Continued Losses Amid Challenging Market Conditions Alpha Cognition ACOG Surges 323 Bullish Momentum Tests Key Resistance Zone LEDS Q1 2026 Earnings Loss Per Share of 007 as Stock Rises 512 OKUR Q1 2026 Earnings Wider EPS Loss Underscores Heavy RD Investment as PreRevenue Biotech Advances Pipeline ALNT Q1 2026 Earnings EPS Falls Short of Estimates Stock Holds Steady QLYS Q1 2026 Earnings EPS Surpasses Estimates by 62 Despite Slight Stock Decline AVXL Q1 2026 Earnings NarrowerThanExpected Loss Amid Continued RD Focus POCI Q1 2026 Earnings Narrowed Loss Reflects Continued Strategic Focus Lisata Therapeutics Q3 2025 Earnings NarrowerthanExpected Loss as Biotech Advances Clinical Pipeline